All Stories

  1. Feedback from the EBF – Focus Workshop: bringing assay validation and analysis of biomarkers into practice

    Article • Bioanalysis, May 2017, Future Science

    Mr Philip Timmerman, John Allinson

  2. The application of capillary microsampling in GLP toxicology studies

    Article • Bioanalysis, April 2017, Future Science

    Mr Philip Timmerman

  3. Biomarker assay validation: are we having the right discussions?

    Article • Bioanalysis, November 2016, Future Science

    Mr Philip Timmerman

  4. Assessment of light stability of drugs in blood and plasma

    Article • Bioanalysis, October 2016, Future Science

    Mr Philip Timmerman

  5. Co-medication and interference testing in bioanalysis: a European Bioanalysis Forum recommendation

    Article • Bioanalysis, October 2016, Future Science

    Mr Philip Timmerman

  6. Best practices for metabolite quantification in drug development: updated recommendation from the European Bioanalysis Forum

    Article • Bioanalysis, June 2016, Future Science

    Mr Philip Timmerman

  7. Microscale bioanalysis

    Article • Bioanalysis, May 2016, Future Science

    Mr Philip Timmerman, Professor Frank A Gomez

  8. Bioanalysis of ibrutinib and its active metabolite in human plasma: selectivity issue, impact assessment and resolution

    Article • Bioanalysis, October 2015, Future Science

    Mr Philip Timmerman

  9. Tiered approach into practice: scientific validation for chromatography-based assays in early development – a recommendation from the European Bioanalysis Forum

    Article • Bioanalysis, September 2015, Future Science

    Mr Philip Timmerman

  10. Scientific or regulated validation: a tiered approach? Meeting report from a joint EBF/DVDMDG workshop

    Article • Bioanalysis, August 2015, Future Science

    Mr Philip Timmerman

  11. Determination of tapentadol and tapentadol-O-glucuronide in human serum samples by UPLC–MS/MS

    Article • Journal of Chromatography B, February 2015, Elsevier

    Mr Philip Timmerman

  12. Implementing Dried Blood Spot Sampling for Clinical Pharmacokinetic Determinations: Considerations from the IQ Consortium Microsampling Working Group

    Article • The AAPS Journal, December 2014, American Association of Pharmaceutical Scientists (AAPS)

    Mr Philip Timmerman

  13. Introduction to the Proposals from the Global Bioanalysis Consortium Harmonization Team

    Article • The AAPS Journal, October 2014, American Association of Pharmaceutical Scientists (AAPS)

    Mr Philip Timmerman

  14. EBF: reflection on bioanalytical assay requirements used to support liquid microsampling

    Article • Bioanalysis, October 2014, Future Science

    Dr Neil Spooner, Mr Philip Timmerman

  15. Feedback from the European Bioanalysis Forum Workshop: taking tiered approach to the next level

    Article • Bioanalysis, October 2014, Future Science

    Mr Philip Timmerman

  16. European Bioanalysis Forum continued plans to support liquid microsampling

    Article • Bioanalysis, July 2014, Future Science

    Dr Neil Spooner, Mr Philip Timmerman

  17. Feedback from a European Bioanalysis Forum survey on bioanalysis of drugs in tissues

    Article • Bioanalysis, June 2014, Future Science

    Mr Philip Timmerman

  18. Recommendations from the European Bioanalysis Forum on method establishment for tissue homogenates

    Article • Bioanalysis, June 2014, Future Science

    Mr Philip Timmerman

  19. Tiered approach: from plan into practice

    Article • Bioanalysis, March 2014, Future Science

    Mr Philip Timmerman

  20. Tiered approach revisited: introducing stage-appropriate or assay-appropriate scientific validation

    Article • Bioanalysis, March 2014, Future Science

    Mr Philip Timmerman

  21. Bioanalysis for plasma protein binding studies in drug discovery and drug development: views and recommendations of the European Bioanalysis Forum

    Article • Bioanalysis, March 2014, Future Science

    Mr Philip Timmerman

  22. Conference Report: AAPS and US FDA Crystal City V meeting on Quantitative Bioanalytical Method Validation and Implementation: feedback from the EBF

    Article • Bioanalysis, March 2014, Future Science

    Mr Philip Timmerman

  23. New Frontiers—Accelerator Mass Spectrometry (AMS): Recommendation for Best Practices and Harmonization from Global Bioanalysis Consortium Harmonization Team

    Article • The AAPS Journal, February 2014, American Association of Pharmaceutical Scientists (AAPS)

    Mr Philip Timmerman

  24. In-depth study of homogeneity in DBS using two different techniques: results from the EBF DBS-microsampling consortium

    Article • Bioanalysis, September 2013, Future Science

    Dr Neil Spooner, Mr Philip Timmerman

  25. LC–MS/MS of large molecules in a regulated bioanalytical environment – which acceptance criteria to apply?

    Article • Bioanalysis, September 2013, Future Science

    Mr Philip Timmerman

  26. The effect of hematocrit on bioanalysis of DBS: results from the EBF DBS-microsampling consortium

    Article • Bioanalysis, September 2013, Future Science

    Mr Philip Timmerman

  27. IS addition in bioanalysis of DBS: results from the EBF DBS-microsampling consortium

    Article • Bioanalysis, September 2013, Future Science

    Mr Philip Timmerman

  28. Update of the EBF recommendation for the use of DBS in regulated bioanalysis integrating the conclusions from the EBF DBS-microsampling consortium

    Article • Bioanalysis, September 2013, Future Science

    Mr Philip Timmerman

  29. Current Regulations for Bioanalytical Method Validations

    Article • August 2013, Wiley

    Mr Philip Timmerman

  30. The European Bioanalysis Forum community’s evaluation, interpretation and implementation of the European Medicines Agency guideline on Bioanalytical Method Validation

    Article • Bioanalysis, March 2013, Future Science

    Mr Philip Timmerman

  31. Managing scientific, technical and regulatory innovation in regulated bioanalysis: a discussion paper from the European Bioanalysis Forum

    Article • Bioanalysis, January 2013, Future Science

    Mr Philip Timmerman

  32. Conference Report: The 3rd EBF Focus Meeting: ‘Hatching’ – emerging technologies approaching the regulated bioanalysis laboratory

    Article • Bioanalysis, December 2012, Future Science

    Mr Philip Timmerman

  33. European Bioanalysis Forum recommendation: scientific validation of quantification by accelerator mass spectrometry

    Article • Bioanalysis, November 2012, Future Science

    Mr Philip Timmerman

  34. European Bioanalysis Forum recommendation on method establishment and bioanalysis of biomarkers in support of drug development

    Article • Bioanalysis, August 2012, Future Science

    Mr Philip Timmerman

  35. Updates from the EBF DBS–microsampling consortium

    Article • Bioanalysis, August 2012, Future Science

    Mr Philip Timmerman

  36. Conference Report: ‘Less is More’: defining modern bioanalysis

    Article • Bioanalysis, March 2012, Future Science

    Mr Philip Timmerman

  37. Conference Report: ‘Large Meets Small’: connecting the bioanalytical community around peptide and protein bioanalysis with LC–MS(/MS)

    Article • Bioanalysis, March 2012, Future Science

    Mr Philip Timmerman

  38. Anticoagulant counter ion impact on bioanalytical LC–MS/MS assay performance: additional validation required?

    Article • Bioanalysis, November 2011, Future Science

    Mr Philip Timmerman

  39. Anticoagulant counter ion impact on bioanalytical LC–MS/MS assays: results from discussions and experiments within the European Bioanalysis Forum

    Article • Bioanalysis, November 2011, Future Science

    Mr Philip Timmerman

  40. EBF and dried blood spots: from recommendations to potential resolution

    Article • Bioanalysis, August 2011, Future Science

    Mr Philip Timmerman

  41. EBF recommendation on the validation of bioanalytical methods for dried blood spots

    Article • Bioanalysis, July 2011, Future Science

    Mr Philip Timmerman

  42. Blood stability testing: European Bioanalysis Forum view on current challenges for regulated bioanalysis

    Article • Bioanalysis, June 2011, Future Science

    Mr Philip Timmerman

  43. Conference Report: From challenges to solutions

    Article • Bioanalysis, April 2011, Future Science

    Mr Philip Timmerman

  44. A screening UHPLC–MS/MS method for the analysis of amyloid peptides in cerebrospinal fluid of preclinical species

    Article • Bioanalysis, January 2011, Future Science

    Mr Philip Timmerman

  45. Conference Report: Connecting strategies on dried blood spots

    Article • Bioanalysis, November 2010, Future Science

    Mr Philip Timmerman

  46. Building the Global Bioanalysis Consortium – working towards a functional globally acceptable and harmonized guideline on bioanalytical method validation

    Article • Bioanalysis, November 2010, Future Science

    Mr Philip Timmerman

  47. Best practices in a tiered approach to metabolite quantification: views and recommendations of the European Bioanalysis Forum

    Article • Bioanalysis, July 2010, Future Science

    Mr Philip Timmerman

  48. Towards harmonized regulations for bioanalysis: moving forward!

    Article • Bioanalysis, April 2010, Future Science

    Mr Philip Timmerman

  49. Request for Global Harmonization of the Guidance for Bioanalytical Method Validation and Sample Analysis

    Article • Bioanalysis, April 2010, Future Science

    Mr Philip Timmerman

  50. Incurred sample reproducibility: views and recommendations by the European Bioanalysis Forum

    Article • Bioanalysis, September 2009, Future Science

    Mr Philip Timmerman

  51. European Bioanalysis Forum and the way forward towards harmonized regulations

    Article • Bioanalysis, August 2009, Future Science

    Mr Philip Timmerman

  52. Darunavir Concentrations in Cerebrospinal Fluid and Blood in HIV-1–Infected Individuals

    Article • AIDS Research and Human Retroviruses, April 2009, Mary Ann Liebert Inc

    Mr Philip Timmerman

  53. Which Human Metabolites Have We MIST? Retrospective Analysis, Practical Aspects, and Perspectives For Metabolite Identification and Quantification in Pharmaceutical Development

    Article • Chemical Research in Toxicology, February 2009, American Chemical Society (ACS)

    Mr Philip Timmerman

  54. Validated LC–MS/MS methods for the determination of risperidone and the enantiomers of 9-hydroxyrisperidone in human plasma and urine

    Article • Journal of Chromatography B, July 2008, Elsevier

    Mr Philip Timmerman

  55. Selection of a Respiratory Syncytial Virus Fusion Inhibitor Clinical Candidate, Part 1:  Improving the Pharmacokinetic Profile Using the Structure−Property Relationship

    Article • Journal of Medicinal Chemistry, September 2007, American Chemical Society (ACS)

    Mr Philip Timmerman

  56. Population pharmacokinetic model of fluvoxamine in rats: Utility for application in animal behavioral studies

    Article • European Journal of Pharmaceutical Sciences, January 2007, Elsevier

    Mr Philip Timmerman

  57. New model for intravenous drug administration and blood sampling in the awake rat, designed to increase quality and throughput for in vivo pharmacokinetic analysis

    Article • Journal of Pharmacological and Toxicological Methods, September 2005, Elsevier

    Mr Philip Timmerman

  58. Synthesis of Novel Diarylpyrimidine Analogues and Their Antiviral Activity against Human Immunodeficiency Virus Type 1

    Article • Journal of Medicinal Chemistry, March 2005, American Chemical Society (ACS)

    Mr Philip Timmerman

  59. Self-assembling PEG-p(CL-co-TMC) copolymers for oral delivery of poorly water-soluble drugs: a case study with risperidone

    Article • Journal of Controlled Release, February 2005, Elsevier

    Mr Philip Timmerman

  60. Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection

    Article • Antiviral Research, November 2003, Elsevier

    Mr Philip Timmerman

  61. Assay Methods for Sufentanil in Plasma

    Article • Anesthesiology, March 1994, Wolters Kluwer Health

    Mr Philip Timmerman

  62. Deuterated Ritanserin analysis by gas chromatography/mass spectrometry: A sensitive technique to study human Ritanserin pharmacokinetics

    Article • Journal of Mass Spectrometry, July 1989, Wiley

    Mr Philip Timmerman

  63. The Use of Stable-Isotope Methodology in Pharmacokinetic Studies Involving Flunarizine

    Article • January 1988, Springer Science + Business Media

    Mr Philip Timmerman

  64. Reliability of Sufentanil Plasma Level Assays in Patients

    Article • Anesthesiology, July 1986, Wolters Kluwer Health

    Mr Philip Timmerman